Skip to main content
. 2015 Jun 9;2015:126408. doi: 10.1155/2015/126408

Figure 1.

Figure 1

Resolvin 1 and sirtuin-1 in clinical development of EIU. Vehicle (saline + ethanol) and resolvin 1 (RvD1, 10–100–1000 ng/kg) were injected into the vitreous of rats 1 hour after vehicle + LPS (200 µg/rat) treatment. Clinical manifestations of EIU were evaluated 24 hours later both with hematoxylin and with eosin (representative pictures of RvD1 1000 ng; magnification: 100x and 200x, scale bar = 100 µm) and scored as reported in text (see Section 2). This figure also shows the effects of pretreatment with compound EX-527, an inhibitor of sirtuin-1 activity (10 mg/kg/day, i.p. for 7 days), prior to LPS and LPS + RvD1 (1000 ng/kg), and the effects of treatment with RvD1 FPR2/ALX Boc2 receptor antagonist (0.4 mg/kg/4 μL) into the vitreous (30 min prior to RvD1 1000 ng/kg). Values are reported as the mean ± S.E.M.; n = 6 observations for each group. ∗ P < 0.05 and ∗∗ P < 0.01 versus LPS-treated rats; °P < 0.01 versus RvD1 1000 ng/kg.